Table 1.

Clinical and laboratory findings in 18 (12.5%) of 144 adults hospitalized with CAP who were positive for M. pneumoniae in any of the laboratory tests used for diagnosis

Patient no. Interval between first symptoms and sampling (days) Antibiotica used before enrollmentAge (yr) Underlying pulmonary disease Titer obtained with: Result of PCR on indicated sampleConcomitant pathogen(s)
MAG test in sample:CFT in sample: NasopharynxThroat swab Throat wash Sputum
1 2 12
1 10 AMZ 33≥160 ≥160 ≥128 ≥128+ + ++ C. pneumoniae
2 12 AMZ 36 <40 ≥160<4 ≥128 + + + + C. pneumoniae
3 5 AMZ 51 <40 <40 <4 32 ++ + +
4 7 Ceph 44 ≥160≥160 ≥128 ≥128 + + +
5 2PEN 45 ≥160 ≥160 4 64 + ++
6 4 48 <40 <40 <4 32+ +
7 6 73COPD <40 <40 4 32 + Parainfluenza virus, H. influenzae
8 14 36 <40 <40 ≥128 64
9 14 38 <40 <40<4 16
10 1 ERY66 COPDNTb NT 8 32NAc NA C. pneumoniae
11 3284 COPD <40 <40 64 64 + S. pneumoniae, L. pneumophila
1213 64 COPD <40 <40 8 8 + H. influenzae
13NA 65 COPD <40 <40 88 +
14 3 CIP 68COPD <40 <40 32 32 +NA
15 3 DOX 70<40 <40 <4 <4 + Adenovirus
16 4 AMC 76 <40 <40 816 + NA Respiratory syncytial virus
17 3 83 COPD <40 <4032 32 + NA S. pneumoniae
18 12 71 <40<40 4 4 +
  • a AMZ, amoxicillin; Ceph, cephalosporin; PEN, penicillin; ERY, erythromycin; CIP, ciprofloxacin; DOX, doxycycline; AMC, amoxicillin-clavulanate.

  • b NT, not tested.

  • c NA, not available.